SCHEMBL12923299

SCHEMBL12923299

CCCCCCCCc1ccc(NC(=O)NC2(CC(=O)O)CCN(C)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.56
▸ EPHX2 P34913 2/20 0.48
▸ EPHX1 P07099 1/20 0.48
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ SPHK1 Q9NYA1 7/20 0.47
▸ THRA P10827 3/20 0.46
▸ THRB P10828 3/20 0.46
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL979212 0.94 S1PR1 (0.50) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL12923341 0.94 S1PR1 (0.54) S1PR1EPHX2EPHX1CA12CA1
Trifluoroacetic Acid SCHEMBL977365 0.89 S1PR1 (0.48) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL979229 0.88 S1PR1 (0.47) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL12923314 0.88 S1PR1 (0.52) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL12923483 0.85 S1PR1 (0.56) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL979213 0.84 S1PR1 (0.43) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL12923362 0.84 S1PR1 (0.56) S1PR1EPHX2EPHX1CA12CA1
Trifluoroacetic Acid SCHEMBL977959 0.83 S1PR1 (0.47) S1PR1EPHX2EPHX1CA12CA1
SCHEMBL12923365 0.83 S1PR1 (0.55) S1PR1EPHX2EPHX1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680282-B2 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2014-03-25 — — US disclosed
US-8680282-B2 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2014-03-25 — — US disclosed
US-20110015174-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2011-01-20 — — US disclosed
WO-2009015485-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015174-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 S1PR1 261/4885EPHX2 4311/4885EPHX1 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback